louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06798285: Comparision of Retinal Function and Macular Structure After 27G Pars Plana Vitrectomy With Minimal Illuminiation
Official title: Comparision of Retinal Function and Macular Structure After 27G Pars Plana Vitrectomy With Minimal Heads-up Versus Standard Illuminiation in Patients With Idiopthic Epiretinal Membranes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Epiretinal Membrane
Lead sponsor: Pomeranian Medical University Szczecin
Sponsor class: OTHER
First posted: 2025-01-29
Enrollment: 40
Sex: ALL
Minimum age (years): 60
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients who met the inclusion criteria were assigned to groups according to block randomization
Primary purpose: TREATMENT

Brief summary: Purpose: To analyze the clinical benefits of using the NGENUITY 3D Visualization System in vitreoretinal surgery with low levels of endo-illumination, focusing on functional and structural retinal protection in patients with idiopathic epiretinal membranes (ERM).

Design: Prospective, randomized, comparative study. Methods: Forty pseudophakic patients (29♀, 11♂; age 60-80 years) with ERM underwent 27G pars plana vitrectomy (PPV) and were randomly divided into two groups: Group I (20 eyes, stand-ard microscope \[Hi-R 900\], endo-illumination 3.2 Lm) and Group II (20 eyes, 3D heads-up NGE-NUITY system, endo-illumination 0.5 Lm). Preoperative and 6-month postoperative evaluations included slit-lamp examination, intraocular pressure (IOP, Pascal tonometer), Distance Best Correct-ed Visual Acuity (DBCVA, logMAR), Central Subfield Thickness (CST), Retinal Nerve Fiber Layer Thickness (RNFL, OCT), Pattern ERG (PERG), multifocal ERG (mfERG), flash ERG (ERG, IS-CEV standards), and retinal sensitivity (HFA macula test). Surgery time, xenon light exposure, ERM/ILM peeling time, fundus autofluorescence (FAF), metamorphopsia incidence, and intra-/postoperative adverse events were analyzed. Results were statistically evaluated (p \< 0.05).


Eligibility criteria: Inclusion Criteria:

* DBCVA \> 0.1 (Snellen charts)
* Pseudophakia
* ERM without other abnormalities
* Patient's consent to participate in the project with a 6-month follow-up after surgery.

Exclusion Criteria:

* Glaucoma
* AMD
* Systemic diseases known to influence retinal function (e.g., diabetes)
* Psychiatric disorders
* Advanced stages of cardiovascular diseases
* Previous PPV
* High myopia.

Primary outcomes:
measure: Bioelectrical Retinal function
timeFrame: 6 months
Secondary outcomes:
measure: Structural Macula Changes
timeFrame: 6 months
measure: Changes DBCVA (Distance Best Corrected vision)
timeFrame: 6 months
Other outcomes:
Locations:
city: Szczecin
country: Poland
facility: II Department of Ophthalmology, Pomeranian Medical University
state: Zachodnipomorskie
Study officials:
References:
Clinical trial NCT00764985: Evaluation of Syncope,Its Diagnosis, Treatment, Outcome and Prognosis
Official title: E-STOP Registry: A Registry for the Evaluation of Syncope,Its Diagnosis, Treatment, Outcome and Prognosis Using Our SELF-Pathway
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Syncope
Keywords: Syncope
Pre-Syncope
Fainting
Lead sponsor: St. Luke's-Roosevelt Hospital Center
Sponsor class: OTHER
Collaborators: name: Transoma Medical
First posted: 2008-10-02
Enrollment: 540
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patietns admitted to the adult medicine service at St. Luke's-Roosevelt Hospital with diagnossi of syncope or near syncope

Brief summary: The investigators want to look at how patients admitted after passing out (syncope) or nearly passing out (pre-syncope) do after going home and how many of them remain free of symptoms of syncope or pre-syncope.


Eligibility criteria: Inclusion Criteria:

* All adult patients (age 18 or older) admitted with syncope or near-syncope

Exclusion Criteria:

* Patients who do not speak/read the language of the consent form
* Prisoners
* Patients who are of altered mental status or had head trauma
* Refusal or inability to sign consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: St. Luke's-Roosevelt Hospital Center
state: New York
Study officials:
References:
Clinical trial NCT01937585: Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA Men
Official title: Evaluation of a Culturally Targeted, Personalized Mail-Home Brochure Directed to Partners of At-Risk Men to Facilitate Prostate Cancer Risk Assessment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostate Cancer
Keywords: prostate cancer
partner
communication messages
monitoring style
AA men
Lead sponsor: Fox Chase Cancer Center
Sponsor class: OTHER
Collaborators: name: Knowledge Networks
First posted: 2013-09-09
Enrollment: 231
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether female partners of African American men can promote initiation of a discussion with a healthcare provider about prostate cancer screening when the partner is supported by a print message designed to provide relevant information and strategies for her to use in this effort.

Detailed description: Objective: Although AA men are at elevated risk for prostate cancer (Pca), medical guidelines do not present consistent screening recommendations for this group. However, all guidelines stress the need for screening decision making with a provider. This study evaluated the effectiveness of a brochure designed for the female partners of AA men, designed to help promote such discussion on the part of their mates. We also explored the effect of the partner's monitoring style (i.e., the extent to which the partner typically attends to health threats) on promoting discussion.

Methods: Female partners of AA men (N=231) were randomized to receive either a Pca screening CDC brochure for AA men, combined with a "partner" brochure containing strategies to promote men's initiation of a provider visit to discuss screening, or the CDC brochure only, and completed pre- and post-intervention surveys online.

Conclusions: High monitoring partners may be effective in influencing their AA mates to initiate provider discussion, particularly when tailored messaging is provided.

Eligibility criteria: Inclusion Criteria:

* U.S. female aged 18 and over, and having an AA male partner between the ages of 35 and 69 with no history of a Pca diagnosis

Exclusion Criteria:

* None

Primary outcomes:
measure: Partner-reported actions of mate to initiate a provider visit to discuss prostate cancer screening
timeFrame: Two weeks post baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
Study officials:
affiliation: Fox Chase Cancer Center
name: Suzanne M Miller, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sajid S, Kotwal AA, Dale W. Interventions to improve decision making and reduce racial and ethnic disparities in the management of prostate cancer: a systematic review. J Gen Intern Med. 2012 Aug;27(8):1068-78. doi: 10.1007/s11606-012-2086-5.
Clinical trial NCT05781685: The Influence of Testosterone on Experimental Pain Perception
Official title: The Influence of Testosterone on Experimental Pain Perception and Social Psychological Functioning
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Acute Pain
Keywords: testosterone
pain tolerance
estradiol
progesterone
Lead sponsor: University of New Mexico
Sponsor class: OTHER
Collaborators: name: American Psychological Association (APA)
First posted: 2023-03-23
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This trial examined how the administration of exogenous testosterone would influence pain tolerance and other endogenous steroids (i.e. estradiol and progesterone).


Eligibility criteria: Inclusion Criteria:

* Healthy college-aged females that are over the age of 18 and younger than 25 will be used for this study.

Exclusion Criteria:

* The following criteria will exclude a participant from the study:
* Anyone that has a tree nut allergy.
* Women that are pregnant or may feel that they may be pregnant or breast-feeding.
* Anyone taking supplements that may influence their testosterone level.
* Anyone taking any kind of steroid that may increase their testosterone level.
* Anyone that smokes tobacco or uses smokeless tobacco.
* Anyone that reports any condition associated with nerve damage.
* Anyone that is using hormonal contraceptive.
* Anyone who was sick or unwell at the time of screening.
* Each participant completed a Testosterone Pre-Screen form. This form asked each participant individually whether they are taking any drugs or have any conditions that might be exacerbated by testosterone. This form was completed before they signed the consent form and each time they arrived in the lab for an experimental session.

Primary outcomes:
measure: Pain Tolerance
timeFrame: 4 hours After Administration
Secondary outcomes:
measure: Changes Testosterone Levels
timeFrame: Prior to Intervention (Baseline), 15 minutes Post Intervention
measure: Changes Estradiol Levels
timeFrame: Prior to Intervention (Baseline), 15 minutes Post Intervention
measure: Changes Progesterone Levels
timeFrame: Prior to Intervention (Baseline), 15 minutes Post Intervention
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: University of New Mexico
state: New Mexico
Study officials:
References:
Clinical trial NCT05586685: Effect of Diaphragmatic Release on Upper Crossed Syndrome
Official title: Effect of Diaphragmatic Release on Upper Crossed Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Neck Muscle Issue
Kyphosis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-10-19
Enrollment: 30
Sex: ALL
Minimum age (years): 17
Maximum age (years): 22
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the study aims to investigate the effectiveness of diaphragmatic release on upper crossed syndrome

Detailed description: Poor posture typically causes upper cross syndrome, resulting in neck pain. Neck pain is the most common reason for patients to visit healthcare professionals. This syndrome can cause dysfunctional tone in posture and muscular disparity of the head, neck, and shoulder region . Evidence suggests that 6-48% of the upper crossed syndrome population complain of pain in the shoulder girdle and cervicothoracic region.

Many disorders are linked with the upper crossed syndrome, including migraine headaches; chronic headaches; Subacromial impingement; biceps tendinitis; thoracic outlet syndrome; degeneration of the cervical spine; and joint dysfunction at the C1-C2 segment, C4-C5 segment, cervicothoracic joint, and T4-T5 segment.

Upon the available research studies, there is no study conducted to investigate the effect of diaphragmatic release on upper crossed syndrome patients.

Eligibility criteria: Inclusion Criteria:

* Age ranged from 17 to 22 years .
* Body Mass Index from 20 to 25 kg/m².
* All participants have an intensity of neck pain on VAS (4-8) (moderate cases).
* The subjects were chosen from both sexes.
* All participants have kyphosis angle ≥42°
* All participants have mechanical neck pain and FHP (craniovertebral angle CVA \< 49).

Exclusion Criteria:

* Malignancy
* Fractures of the cervical spine
* Cervical radiculopathy or myelopathy
* Vascular syndromes such as vertebrobasilar insufficiency
* Rheumatoid arthritis
* Neck or upper back surgery
* Taking anticoagulants
* Local infection
* Whiplash injury

Primary outcomes:
measure: chest expansion with tape measurement
timeFrame: up to four weeks
Secondary outcomes:
measure: pain intensity with pain numerical scale scale
timeFrame: up to four weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04636385: Jumping Gap Dimension at Maxillary Teeth: Cone-Beam Computed Tomography (CBCT) Study
Official title: Assessment of Jumping Gap Dimension at Maxillary Teeth in Addition to Selected Anatomical Landmarks Related to Immediate Implant Placement in the Esthetic Zone: Observational Cone-Beam Computed Tomography (CBCT) Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Jumping Gap Dimension at Maxillary Teeth
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-11-19
Enrollment: 253
Sex: ALL
Minimum age (years): 15
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Egyptian Population (Cairo Residents)

Brief summary: To assess the important anatomical structures involved in the treatment planning of immediate implants, particularly the jumping gap distance at the different maxillary teeth in the esthetic zone using CBCT analysis. Additional relevant radiographic aspects are evaluated as well to aid in decision making related to immediate implants.


Eligibility criteria: Inclusion Criteria:

* teeth at upper jaw including : incisors, laterals, canines and premolars

Exclusion Criteria:

* teeth having: extensive restorations, crowns, implants
* CBCT scans showing scattering
* teeth showing bone loss around them indicative of periodontal disease

Primary outcomes:
measure: Jumping gap
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
state: Greater Cairo
Study officials:
affiliation: Cairo University
name: Hani El Nahass, PhD
role: STUDY_DIRECTOR
References:
citation: Araujo MG, Sukekava F, Wennstrom JL, Lindhe J. Ridge alterations following implant placement in fresh extraction sockets: an experimental study in the dog. J Clin Periodontol. 2005 Jun;32(6):645-52. doi: 10.1111/j.1600-051X.2005.00726.x.
citation: Botticelli D, Berglundh T, Lindhe J. Hard-tissue alterations following immediate implant placement in extraction sites. J Clin Periodontol. 2004 Oct;31(10):820-8. doi: 10.1111/j.1600-051X.2004.00565.x.
citation: Lee SL, Kim HJ, Son MK, Chung CH. Anthropometric analysis of maxillary anterior buccal bone of Korean adults using cone-beam CT. J Adv Prosthodont. 2010 Sep;2(3):92-6. doi: 10.4047/jap.2010.2.3.92. Epub 2010 Sep 30.
Clinical trial NCT06760585: Prognostic Factors Associated With Failure of Total Elbow Replacement
Official title: Prognostic Factors Associated With Failure of Total Elbow Replacement: a Protocol for Analysis of National Joint Registry Data
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Total Elbow Replacement
Lead sponsor: University of Manchester
Sponsor class: OTHER
Collaborators: name: The National Joint Registry
name: The Royal College of Surgeons of England
name: John Charnley Trust
name: University of Bristol
First posted: 2025-01-07
Enrollment: 4073
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with a primary total elbow replacement in England on the National Joint Registry (NJR)

Brief summary: This observational study aims to evaluate potential prognostic factors for TER failure . The National Joint Registry (NJR) currently contains the largest elbow registry dataset in the world, which has been shown to have high completeness and accuracy. In order to incorporate additional potential prognostic factors not captured in the NJR, this study will combine the NJR elbow dataset with the NHS England Hospital Episode Statistics-Admitted Patient Care (HES-APC) data. Understanding prognostic factors is a crucial step for informing the development of strategies aimed at minimising the risk of failure and the necessity for additional surgery, which poses a burden on patients and society.


Eligibility criteria: Inclusion Criteria:

All patients aged 16 to 100 years old with a primary TER on the National Joint Registry (NJR) elbow dataset from the start of data collection on the 1st of April 2012 to the 31st of December 2023 will be included.

Exclusion Criteria:

Patients are excluded if they did not consent for their data to be used for research purposes, if it is impossible to trace them after surgery, if their ID numbers are invalid, or if the surgery was not performed in England.

Unconfirmed procedures and procedures with inconsistent operative patterns (i.e. a sequence of operations where the primary operation is not the first operation in the sequence or where there are multiple primary operations recorded for the same joint) will be excluded from the analyses.

Primary outcomes:
measure: The hazard of failure of total elbow replacement
timeFrame: 11 years
Secondary outcomes:
Other outcomes:
Locations:
city: Manchester
country: United Kingdom
facility: Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre
Study officials:
References:
Clinical trial NCT00280085: The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.
Official title: Pancreatic Beta-Cell Mass And Function Quantification By Means Of Perfusion Imaging
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Diabetes Mellitus
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
Collaborators: name: Yale University
First posted: 2006-01-20
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Assess pancreatic beta cell function using MR imaging.

Detailed description: The study was terminated on July 31st, 2007. The study was discontinued, as we have not met the primary end point, differentiation between normal volunteers and subjects with type 1 diabetes mellitus. There were no safety concerns.

Eligibility criteria: Inclusion Criteria:

* Normal Volunteers
* T1DM and T2DM subjects

Exclusion Criteria:

* Concomitant severe conditions

Primary outcomes:
measure: Pancreatic perfusion
Secondary outcomes:
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Pfizer Investigational Site
state: Connecticut
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
citation: Hirshberg B, Qiu M, Cali AM, Sherwin R, Constable T, Calle RA, Tal MG. Pancreatic perfusion of healthy individuals and type 1 diabetic patients as assessed by magnetic resonance perfusion imaging. Diabetologia. 2009 Aug;52(8):1561-5. doi: 10.1007/s00125-009-1406-8. Epub 2009 Jun 3.
Clinical trial NCT02296385: Genotype-related Effects of PUFA
Official title: Response to PUFA Intervention According to PPAR Genotypes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: volunteers
Lead sponsor: Société des Produits Nestlé (SPN)
Sponsor class: INDUSTRY
First posted: 2014-11-20
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: To assess the bioefficacy of omega-3 fatty acids (provided by intake of fish oil supplements) depending on genotype of relevant factors in lipid metabolism

Detailed description: To assess the bioefficacy of omega-3 fatty acids (provided by intake of fish oil supplements) depending on genotype of relevant factors in lipid metabolism.

Eligibility criteria: Inclusion Criteria:

* Healthy adult between 18 and 40 years of age
* BMI between 18.5 and 30 kg/m2
* Sedentary to moderate physical activity habits

Exclusion Criteria:

* Concomitant treatment: Consumption of dietary supplements or any medication that can affect the study outcomes
* Actively smoking
* Suspected abuse of alcohol or illicit drugs
* Significant illness within the two weeks prior to study start or any active systemic infection or medical condition that may require treatment during the study
* Known or suspected medical condition related to coagulation
* Subject who cannot be expected to comply with the study procedures
* Currently participating or having participated in another clinical trial during the last 4 weeks prior to beginning of this study

Primary outcomes:
measure: Changes in triglyceride levels in plasma
timeFrame: Baseline and 6 weeks intervention
Secondary outcomes:
measure: Assess bioefficacy of EPA and DHA supplementation
timeFrame: Baseline and 6 weeks intervention
Other outcomes:
Locations:
Study officials:
affiliation: Instituto Nacional de Medicina Genomica
name: Maria Elizabeth Tejero Barrera, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Binia A, Vargas-Martinez C, Ancira-Moreno M, Gosoniu LM, Montoliu I, Gamez-Valdez E, Soria-Contreras DC, Angeles-Quezada A, Gonzalez-Alberto R, Fernandez S, Martinez-Conde D, Hernandez-Moran B, Ramirez-Solano M, Perez-Ortega C, Rodriguez-Carmona Y, Castan I, Rubio-Aliaga I, Vadillo-Ortega F, Marquez-Velasco R, Bojalil R, Lopez-Alvarenga JC, Valet P, Kussmann M, Silva-Zolezzi I, Tejero ME. Improvement of cardiometabolic markers after fish oil intervention in young Mexican adults and the role of PPARalpha L162V and PPARgamma2 P12A. J Nutr Biochem. 2017 May;43:98-106. doi: 10.1016/j.jnutbio.2017.02.002. Epub 2017 Feb 10.